The Biologue CGM includes a skin-adhered sensor module with a small intradermal sensor, which measures glucose in interstitial fluid.
The sensor module sends data up to 10 feet to a proprietary handheld monitor or personal computer for display and analysis.
The trial conducted at the State University of New York (SUNY) Upstate Medical University demonstrated that the Ultradian’s Biologue CGM exhibits a high degree of accuracy as compared to available CGM devices.
Ultradian said it has also collaborated with the University at Albany’s College of Nanoscale Science and Engineering (CNSE) to launch its advanced research and pilot prototyping technology.
Ultradian Diagnostics CEO John Willis said the ability to partner with CNSE, including its Smart System Technology and Commercialization Center, is a critically important step forward in providing access to capabilities that will accelerate commercialization.
SUNY Upstate Medical University Endocrinology, Diabetes and Metabolism chief and principal investigator Ruth Weinstock said they are impressed with Ultradian’s CGM and excited by the results of this pilot study and believe this new technology could greatly benefit patients with diabetes, and move them forward in the development of the artificial pancreas.
